Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2369-2376

  Tavornvipas, Sumitra ^a   Tajiri, Shinichiro ^a   Hirayama, Fumitoshi ^a   Arima, Hidetoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Aggregation; Deamidation; Hydrophilic cyclodextrin; Hydrophobic interaction; Oxidation; Recombinant human growth hormone

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CYCLODEXTRIN; GAMMA CYCLODEXTRIN; GUANIDINE; HUMAN GROWTH HORMONE;

ARTICLE; DEAMINATION; DENATURATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG INDUSTRY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE PROTEIN COMPLEX; HYDROPHILICITY; HYDROPHOBICITY; OXIDATIVE STRESS; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS; SOLUBILITY; SURFACE PROPERTY; TECHNIQUE; THERMAL ANALYSIS; ULTRAVIOLET SPECTROPHOTOMETRY; VORTEX MOTION;

CYCLODEXTRINS; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS;

EID: 17644384876     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7691-5     Document Type: Article

References (26)

1. H. LeVine 3rd and J. D. Scholten. Screening for pharmacological inhibitors of amyloid fibril formation. Methods Enzymol. 309: 467-476 (1999).
2. C. M. Dobson. Protein folding and misfolding. Nature 426:884-890 (2003).
3. S. W. Raso and J. King. Protein folding and human disease. In R. H. Pain (ed.), Mechanisms of Protein Folding, IRL Press, Oxford, 2000 pp. 406-428.
4. J. L. Cleland, M. F. Powell, and S. J. Shire. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carr. Syst. 10:307-377 (1993).
5. M. C. Manningm, K. Patel, and R. T. Borchardt. Stability of protein pharmaceuticals. Pharm. Res. 6:903-918 (1989).
6. N. Karuppiah and A. Sharma. Cyclodextrins as protein folding aids. Biochem. Biophys. Res. Commun. 211:60-66 (1995).
7. L. Szente and J. Szejtli. Highly soluble cyclodextrin derivatives: chemistry, properties and trends in development. Adv. Drug Deliv. Rev. 36:17-28 (1999).
8. K. Uekama, F. Hirayama, and T. Irie. Cyclodextrin drug carrier system. Chem. Rev. 98:2045-2076 (1998).
9. K. Tokihiro, T. Irie, and K. Uekama. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution. Chem. Pharm. Bull. (Tokyo) 45:525-531 (1997).
10. K. Matsubara, Y. Ando, T. Irie, and K. Uekama. Protection afforded by maltosyl-β-cyclodextrin against α-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate. Pharm. Res. 14:1401-1405 (1997).
11. M. E. Brewster, M. S. Hora, J. W. Simpkins, and N. Bodor. Use of 2-hydroxypropyl- β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8:792-795 (1991).
12. R. L. Scott. Some comments on Benesi-Hildebrand equation. Rec. Trav. Chim 75:787-789 (1956).
13. G. Teshima and E. C. Davis. Separation of oxidized human growth hormone variants by reversed-phase high-performance liquid chromatography: Effect of mobile phase pH and organic modifier. J. Chromatogr 625:207-215 (1992).
14. J. L. Cleland, A. Mac, B. Boyd, J. Yang, E. T. Duenas, D. Yeung, D. Brooks, C. Hsu, H. Chu, V. Mukku, and A. J. S. Jones. The stability of recombinant human growth hormone in poly (lactic-co-glycolic acid) (PLGA) microsphere. Pharm. Res. 14:420-425 (1997).
15. N. B. Bam, J. L. Cleland, and T. W. Randolph. Molten globule intermediate of recombinant human growth hormone: Stabilization with surfactants. Biotechnol. Prog. 12:801-809 (1996).
16. M. Dadlez. Hydrophobic interactions accelerate early stages of the folding of BPT1J. Biochemistry 36:2788-2779 (1997).
17. T. Arakawa and S. N. Timasheff. Stabilization of protein structure by sugars. Biochemistry 21:6536-6544 (1982).
18. D. E. Otzen, B. R. Knudsen, F. Aachmann, K. L. Larsen, and R. Wimmer. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci. 11:1779-1787 (2002).
19. W. C. Cromwell, K. Byström, and M. R. Eftink. Cyclodextrinadamantanecarboxylate inclusion complexes: Studies of the variation in cavity size. J. Phys. Chem. 89:326-332 (1985).
20. I. Jelesarov and H. R. Bosshard. Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition. J. Mol. Recognit. 12:3-18 (1999).
21. I. G. Orellana, B. Variano, J. M. Fraboni, S. Milstein, and D. R. Paton. Thermodynamic characterization of an intermediate state of human growth hormone. Protein Sci. 7:1352-1358 (1998).
22. M. Katanam. L. N. Bell, and A. K. Banga. Effect of surfactants on the physical stability of recombinant human growth hormone. J. Pharm. Sci. 84:713-716 (1995).
23. S. Tavornvipas, F. Hirayama, H. Arima, K. Uekama, T. Ishiguro, M. Oka, K. Hamayasu, and H. Hashimoto. 6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl- β-cyclodextrin: Solubilizing ability and some cellular effects. Int. J. Pharm. 249:199-209 (2002).
24. S. A. Charman, K. L. Mason, and W. N. Charman. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm. Res. 10:954-962 (1993).
25. R. A. Houghten, C. B. Glaser, and C. H. Li. Human somatotropin reaction with hydrogen peroxide. Arch. Biochem. Biophys. 178: 30-355 (1977).
26. R. Pearlman and T. A. Bewley. In J. Y. Wang and R. Pearlman (eds.), Stability and Characterization of Protein and Peptide Drugs: Case Histories, Plenum Press, New York, 1993, pp.1-58.